A new genetic target for Alzheimer’s treatments

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...

2025: Breakthroughs and highlights

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...

Could neural stem cells be driving brain tumour recurrence?

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...

Advances in MS research that you should know about

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...

A smartphone app hopes to move Parkinson’s research forward

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...

First-in-Canada RNA trial for rare ataxia launches at The Neuro

About Us CRU Directors CRU Investigators Leading Trial Site Clinical Trials Information for Patients ALS Brain Tumour Dementia Epilepsy Intensive Care Unit Movement Disorders Multiple Sclerosis Neuromuscular Stroke ASHG SYMPOSIUM Program Abstracts Registration...